

SITC 2016

NATIONAL HARBOR, MD
NOVEMBER 9-13, 2016

Humanized mice models of cancer immunotherapy

Karolina Palucka, MD, PhD

The Jackson Laboratory for Genomic Medicine
Farmington, CT



Society for Immunotherapy of Cancer

#SITC2016

Presenter Disclosure Information

Karolina Palucka, MD, PhD

The following relationships exist related to this presentation:

Merck : Consulting, pending grant support


#SITC2016

Approach to construction of humanized mice

- Adoptive transfer of human cells
- Transplant of human hematopoietic cells with or without accessory tissues in conditioned immunodeficient host
- Genetic editing of immunodeficient hosts
- Genetic editing of immunocompetent mice

Major Humanized Mice Strain Platforms




NSG	NOD-<i>scid IL2rg^{null}</i>	Jackson Laboratory
NOG	NOD-<i>scid IL2rg^{Trunc}</i>	CIEA (Tokyo)
NRG	NOD-<i>Rag1^{null} IL2rg^{null}</i>	Jackson Laboratory
BRG	BALB/c-<i>Rag2^{null} IL2rg^{null}</i> "MISTRG" Rongvaux, 2014 <i>Nat Biotech</i> 32;364	Yale/Univ. Hosp. Zurich
H2 ^d RG	Stock-H2^d-<i>Rag2^{null} IL2rg^{null}</i>	Pasteur Institute
C57BL/6	<i>Rag2^{null} IL2rg^{null} CD47^{null}</i>	NIAID/Stanford Univ.





Use cases

1st generation Onco-Humice


Bell et al, J Exp Med 1999




From patients to 1st generation Onco-Humice
back to patients




Tumor promoting inflammation in breast cancer



IL1 blockade prevents breast cancer progression




IL1 β upregulation in breast cancer is clinically relevant




Connie Xu, Tina Wu

Patients with high IL1 β transcription in breast cancer have decreased long-term survival



Adoptive T cell transfer



NOD-SCID $\beta 2m^{-/-}$ mouse
Adult CD34 $^{+}$ HPCs

Palucka et al., Blood 2003

Yu et al., Blood 2008

Yu et al. Immunity, 2013


Graham et al. Vaccine 2016.

Aspord C, J Exp Med 2007

Pedroza-Gonzalez, J Exp Med 2011

Wu et al, Cancer Immunol Res 2013

Endogenous T cells



NOD-SCID $\gamma c^{-/-}$ or $Rag2^{-/-}\gamma c^{-/-}$ mouse
Fetal CD34 $^{+}$ HPCs &
thymus and liver

MISTRG: Human M-CSF/IL-3, GM-CSF/SCF/SIRPa/TPO

NSG-SGM3:SCF/GM-CSF, IL-3

DRAG: HLA-DR4

NSG-A2: HLA-A2.1

Traggiai et al., Science 2004

Shultz et al., JI 2005

Melkus et al., Nat Med 2006


Billerbeck et al., Blood 2011

Rongvaux et al, Nat Biotech 2014

2nd generation humanized mice: Genetic humanization of cytokine encoding genes

M-CSF^{h/h}
IL-3/GM-CSF^{h/h}
hSirpa^{tg}
TPO^{h/h}
RAG2^{-/-}
IL2RGamma^{-/-}

Myeloid development
Phagocytic tolerance
Longterm maintenance of functional HSCs
Immunosuppression (no mouse T, B, NK cells)




Rongvaux et al., Nat. Biotech., 2014

Development and function of human innate immune cells in a humanized mouse model

Anthony Rongvaux^{1,10}, Tim Willinger^{1,10}, Jan Martinek^{2,3}, Till Strowig^{1,9}, Sofia V Gearty¹, Lino L Teichmann^{4,5}, Yasuyuki Saito⁶, Florentina Marches², Stephanie Halene⁷, A Karolina Palucka², Markus G Manz⁶ & Richard A Flavell^{1,8}


Functional human monocytes and macrophages



Human melanoma


NATURE BIOTECHNOLOGY ADVANCE ONLINE PUBLICATION

published online 16 March 2014; doi:10.1038/nbt.2858




Macrophage infiltrate in experimental and patient tumor



MISTRG



PATIENT




DNA
HLA-DR
CD163



DNA
CD163
CD206


Anthony Rongvaux^{a*}, Tim Willinger^{a*}, Jan Martinek et al. Nat Biotechnology 2014

Capture of tumor antigens in experimental melanoma tumors



DAPI
CD206
CD163
gp100

Reprogramming antigen presentation in tumors from antigen degradation to antigen presentation




Applying humanized mice to studies on checkpoint inhibitors

- Hu-NSG & Hu-NSG-SGM3
- PDX or human cancer cell engrafted
 - Partial HLA match
 - CD34 donor variability; utilize multiple donors
 - Anti-PD-1, CTLA-4,
 - ~15% PDX tumor rejection
 - ~85% PDX/ cell line tumor growth
 - ~70% of these we have statistically significant tumor growth reduction with keytruda treatment
 - 100% statistical significant decrease in tumor PD-1 detection with keytruda treatment


JAX – In Vivo Pharmacology Services

Jim Keck, Minan Wang, Li-Chin Yao, Mingshan Cheng and Danying Cai



Humanized breast cancer PDX Evaluating the effect of anti-PD-1




**Humanized NSG (HuNSG) with Tumor
(human immune system and human tumor)**



Evaluating the Effects of anti-PD-1 on breast cancer CDX in humanized NSG mice









Efficacy of PD-1 blockade in humanized NSG mice bearing breast cancer CDX is CD8⁺ T Cell Dependent




***P<0.0001; two-way ANOVA followed by Bonferroni post-tests.

Immunotherapy changes the tumor immune infiltrate




Jan Martinek

Better reconstitution of human cells in the blood of NSG-SGM3 (SCF GM-CSF IL-3) mice than NSG mice




Junni Yu

Humanized NSG-SGM3 mice favor the development of CD4+ T cells




Junni Yu

CD11b⁺ myeloid compartment in periphery of hNSG-SGM3 mice



Junni Yu

Preliminary Efficacy Results of TNBC PDX in HuCD34 NSG-SGM3 Mice




Jim Keck, Li-Chin Yao

Examples of progress in the field on humanized mice based on host modification

- Richard Flavell: next generation MISTRG mice with IL15&IL15Ra
- Madhav Dhodapkar: MISTRG6 for B cell malignancy
Nat Med Nov 2016
- Susann Rahmig: NSG with mouse kit mutant ($\text{Kit}^{\text{w}41}$) for engraftment *Cell Stem Cell 2014*
- Roberta Pelanda: BAFF for Ab
- Dale Greiner: NSG-SGM3 with CSF1-tg for macrophages and IL2-tg for NK cells
- Inessa Schwab: NSG-FcRg-ko for IVIG **Cell Rep. 2015**


NSG with mouse kit mutant ($\text{Kit}^{\text{W}41}$)

- Human HSCs engraft efficiently into adult immune-deficient Kit mutant mice
- *Kit* mutation enables human HSC engraftment without irradiation conditioning
- Human HSCs show robust multilineage engraftment and self-renewal in mice



BRG with mouse Flt3 mutant (BRGF)


- BRGF mice have reduced cDC and pDC compartments, increased Flt3L levels and deficit to Flt3L stimulation
- Human cDCs and pDCs develop from hCD34+ precursors can be specifically boosted with exogenous Flt3L
- Increased human T and NK-cell homeostasis after boosted with exogenous Flt3L




Li et al., Eur J Immunol 2016

Modified NSG mice via CRISPR-Cas mediated genome editing

Knockout Models – NHEJ Mediated by CRISPR



Knock-in Models – HDR Mediated by CRISPR



JAX Laboratories: Next Generation of Humanized Mice

CRISPR editing of the host and of human cells

Tg expression of human factors

Cytokines
HLA molecules
Microenvironmental factors
(SIRPa)
Hormones (prolactin)

Reduction of mouse immunity

H2 molecules
Thymus
Macrophages
Granulocytes
Dendritic Cells
Chemokine receptors
Interferon receptors
Toll-like receptors


Human cancer models

Leukemias and lymphomas
Solid tumors
Role of human stroma

Shultz Nat Rev Immunol 2012

Current challenges

- **Mouse thymic environment and human T cell maturation and selection**
- **Practical constraints in making autologous humanized mice**
- **Source of HPCs: bone marrow, blood, iPS**
- **The variance in microbiome**



Design the experiment
Design the mice

Thanks to our patients

Thanks to funding organizations

Chun Yu
Jan Martinek
Florentina Marches
Te-Chia Wu
Patrick Metang
John Graham
Pierre Authie
.....

Jim Keck and colleagues at JAX Sacramento
Susie Airhart

Lenny Shultz
Carol Bult
....and many colleagues at JAX MG

Anthony Rongvaux
Richard Flavell
....and many external collaborators

Jacques Banchereau